MARKET

TARO

TARO

Taro Pharm
NYSE

Real-time Quotes | Nasdaq Last Sale

63.11
-1.03
-1.61%
Closed 16:00 08/13 EDT
OPEN
63.62
PREV CLOSE
64.14
HIGH
64.22
LOW
62.65
VOLUME
12.93K
TURNOVER
--
52 WEEK HIGH
99.69
52 WEEK LOW
56.07
MARKET CAP
2.41B
P/E (TTM)
-9.3603
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TARO stock price target is 82.00 with a high estimate of 82.00 and a low estimate of 82.00.

EPS

TARO News

More
Taro Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results on Wednesday.
Benzinga · 07/30 13:44
Taro Pharmaceutical (TARO) Misses Q1 Earnings and Revenue Estimates
Taro (TARO) delivered earnings and revenue surprises of -34.48% and -25.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/29 22:55
Taro Provides Results for Quarter Ended June 30, 2020
TARO PROVIDES RESULTS FOR QUARTER ENDED JUNE 30, 2020
Business Wire · 07/29 21:00
Taro Pharmaceutical EPS of -$11.37
Seeking Alpha · 07/29 04:00
Taro Pharma settles U.S. price-fixing charges
Taro Pharmaceuticals (NYSE:TARO) says it agrees to pay ~$205M to settle allegations by the Department of Justice that it conspired to fix prices and rig bi
seekingalpha · 07/24 03:42
Taro Says Has Resolved All Cases Involving Co. In Connection With In DOJ Antitrust Investigations
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that its wholly-owned subsidiary, Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”),
Benzinga · 07/23 20:33
Taro Achieves Global Resolution of DOJ Antitrust Investigations
Taro Achieves Global Resolution of DOJ Antitrust Investigations
Business Wire · 07/23 20:32
Taro to Announce First Quarter Results on July 29, 2020
Taro To Announce First Quarter Results on July 29, 2020
Business Wire · 07/22 18:37

Industry

Pharmaceuticals
-0.43%
Pharmaceuticals & Medical Research
-0.01%

Hot Stocks

Symbol
Price
%Change

About TARO

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.
More

Webull offers kinds of Taro Pharmaceutical Industries Ltd. stock information, including NYSE:TARO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TARO stock methods without spending real money on the virtual paper trading platform.